IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Trial details
- Registry ID
- NCT06112314
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as IMC-F106C
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)NCT06112314 | Immunocore Ltd | Phase 3 | Recruiting | 2027-10-16Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |